AI-Integrated Hydrophobic Auristatin F Compounds for Enhanced Cancer Treatment

The invention integrates hydrophobic Auristatin F compounds with cutting-edge technologies such as AI, IoT, blockchain, and novel materials to create a more effective and targeted cancer treatment system.

The original patent disclosed hydrophobic Auristatin F compounds with activity against MDR+ cancer cells, but lacked the ability to selectively target cancer cells and monitor treatment outcomes in real-time. The new inventive concept addresses these limitations by incorporating AI-powered diagnostics, IoT-enabled wearable devices, blockchain-based tracking, and novel material-based linkers to enhance treatment efficacy and patient safety.

The new system comprises a hydrophobic Auristatin F compound conjugate integrated with an AI-powered diagnostic module that selectively targets MDR+ cancer cells with higher copy number of the targeted antigen. The conjugate is administered in combination with an IoT-enabled wearable device that monitors and adjusts the dosage based on real-time biomarker data. Additionally, the system includes a blockchain-based tracking system to ensure the authenticity and provenance of the conjugate throughout the supply chain. The kit for preparing the conjugate includes a novel material-based linker that enhances the stability and efficacy of the conjugate.

The new claims introduce the concept of integrating hydrophobic Auristatin F compounds with AI, IoT, blockchain, and novel materials, which is not obvious from the original patent. The inventive step lies in the synergistic combination of these technologies to create a more effective and targeted cancer treatment system.

Alternative embodiments of the inventive concept could include integrating the hydrophobic Auristatin F compounds with other AI-powered diagnostic tools, such as machine learning-based algorithms for predicting treatment outcomes. Variations could include using different types of IoT-enabled devices or blockchain-based tracking systems to monitor and adjust treatment regimens.

The inventive concept has significant commercial potential in the cancer treatment market, particularly in the areas of targeted therapy and personalized medicine. The integration of AI, IoT, blockchain, and novel materials could lead to more effective and efficient treatment regimens, improving patient outcomes and reducing healthcare costs.